Alexion Pharma (ALXN) on Watch After Voluntary Recall

August 20, 2013 8:39 AM EDT Send to a Friend
On August 19, 2013, Alexion Pharma (Nasdaq: ALXN) International Sárl, a subsidiary of Alexion Pharmaceuticals, Inc., initiated a voluntary recall and replacement of the remaining vials of a single lot of Soliris® (eculizumab) due to the presence of visible particles in a limited number of vials in this single lot. Alexion estimates that the portion of the current affected lot being replaced in hospitals represents approximately 1-2% of the monthly vial consumption. The particles were recently observed by Alexion as part of its routine testing of retained samples following vial filling, packaging, and labeling by a third party contract vialer that began performing services for Alexion in 2012.

Based on current information, Alexion believes that the supply of Soliris to patients will not be interrupted. Alexion continues to use its other third party contract vialer, as it has since 2009, for worldwide distribution of Soliris. Visible particles have not been observed in lots filled at this other third party contract vialer. Alexion has also initiated filling, packaging, and labeling with another contract vialer which is expected to be approved for distribution later in 2013. In addition, Alexion has engaged a fourth contract vialer for filling, packaging, and labeling of Soliris, which is expected to be approved in 2014.

Alexion continues to analyze the relevant information to investigate the cause of this observation. To date, there has not been any identifiable safety concern attributed to this single lot. Prior to the recent observation, post-release testing from the affected lot met quality specifications. All other lots from the same third party contract vialer continue to meet quality specifications in post-release testing. Alexion is not planning to fill new vials with this third party contract vialer at this time, but may do so in the future.

Alexion has voluntarily instructed its distributors to withhold and replace the remaining vials of the affected lot. The affected lot was filled in June 2012, and first distributed in December 2012 in countries outside the United States. Alexion estimates that vials from this lot on the market immediately prior to notifying distributors represent less than 1% of Alexion's total inventory.

Alexion has notified the European Medicines Agency and other health authorities as required.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Trader Talk

Add Your Comment